非小细胞肺癌患者中外周血浆K-ras基因突变的研究

Detection of K-ras Gene Mutations in Peripheral Blood Free DNA in Patients with Non-Small Cell Lung Cancer

目的比较四川地区非小细胞肺癌患者外周血浆游离DNA与肺癌组织K-ras基因突变的一致性,探讨外周血K-ras检测的临床价值。方法应用突变富集液相芯片检测技术比较242例非小细胞肺癌患者的肺癌组织、外周血浆游离DNA中的K-ras基因突变检出率,观察血浆检测与组织检测的一致性。结果在本组242例非小细胞肺癌病例中,肺癌组织中检测出K-ras基因突变者共有12例患者,检出率为4.96%,外周血浆中检出10例K-ras基因突变,检出率为4.13%。外周血浆游离DNA中的K-ras基因突变检出率与肺癌组织中的检出率具有较好的一致性(Kappa值=0.81)。结论非小细胞肺癌患者外周血浆游离DNA中的K-ras可替代肺癌组织进行K-ras基因突变的筛查。

Objective To investigate the clinical significancy of K-ras gene mutation in peripheral blood free DNA in patients with non-small cell lung cancer （NSCLC）. Methods A total of 242 patients pathologically diagnosed with NSCLC in the Third People＇ s Hospital of Chengdu were recruited between January 2013 and August 2015. Both tumor tissues and peripheral blood free DNA were collected for detection of K-ras gene mutation by mutant-enriched liquidchip technology. The detection rate was compared between these two kinds of samples. Results In tumor tissues,the K-ras gene mutation was detected in 12 cases with a positive rate of 4. 96%. While in peripheral blood samples, the K-ras gene mutation was detected in 10 cases with a positive rate of 4. 13%. The detection yield of K-ras gene mutation in peripheral blood had a good consistency with that of lung cancer tissues （ Kappa value = 0. 81 ）. Conclusion K-ras in peripheral blood plasma free DNA can be a surrogate marker for tumor tissues＇ K-ras gene mutation in screening patients with NSCLC.